Hypertension – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertension (US)

Hypertension is one of the most common medical conditions in the world, and in the United States, the Centers for Disease Control and Prevention estimates that 116 million people have it. A wide array of agents are available both as monotherapy and in fixed-dose combinations to treat the disease. RAAS inhibitors (ACE inhibitors and ARBs), diuretics, and calcium channel blockers are the most commonly used first-line agents. The majority of antihypertensive agents are generically available and thus are cost-effective. Using a longitudinal claims data analysis, we demonstrate how newly diagnosed and recently treated hypertensive patients receive pharmacotherapy in the United States.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed hypertensive patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed hypertensive patients?
• How have peripherally acting alpha-adrenergic blockers been integrated into the treatment algorithm, and what is their source of business?
• What percentage of hypertensive patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
• What percentage of hypertensive patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Noden Pharma, Pfizer, Novartis

Key drugs: ACE inhibitors, Beta blockers, ARBs

SOLUTION ENHANCEMENT

The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.